FDA Grants Orphan Drug Designation (ODD) for Xeris Pharmaceuticals’ Ready-to-Use Glucagon for the Treatment of Hyperinsulinemic Hypoglycemia (HH). Results from Phase 2a Study in Post-Bariatric Hypoglycemia, Associated with HH, Published.

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement